|
T10746 |
CDK9-IN-8
|
|
CDK
|
|
CDK9-IN-8 is a highly potent and selective CDK9 inhibitor (IC50: 12 nM). |
|
T10745 |
CDK9-IN-7
|
|
CDK
|
|
CDK9-IN-7 is a highly selective and orally active CDK9/cyclin T inhibitor (IC50: 11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD: 148 nM; CDK6/cyclinD: 145 nM). |
|
T10742 |
CDK9-IN-10
|
|
CDK
|
|
CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2. |
|
T62235 |
CDK-IN-9
|
|
|
|
CDK-IN-9 (compound 24) is a potent inhibitor of CDK. CDK-IN-9 is also a molecular gel that induces interaction between CDK12 and DDB1 and is able to act on CDK2/E (IC50: 4 nM). CDK-IN-9 can be used to dephosphorylate ret... |
|
T14918 |
CDK9-IN-2
|
|
Others
,
CDK
|
|
|
|
T10747 |
CDK9-IN-9
|
|
CDK
|
|
CDK9-IN-9 is a potent and selective CDK9 inhibitor (IC50: 1.8 nM) with anti-cancer activity. It inhibits CDK2 (IC50: 155 nM). |
|
T40047 |
CDK6/9-IN-1
|
CDK6/9-IN-1 |
|
|
CDK6/9-IN-1 (compound 66) is a potent dual inhibitor of CDK 6 and CDK 9 that can be administered orally. It exhibits inhibitory activity with IC 50 values of 40.5 nM and 39.5 nM against CDK6 and CDK9, respectively. |
|
T40353 |
CDK7/9-IN-1
|
CDK7/9-IN-1 |
|
|
CDK7/9-IN-1 is a specific inhibitor of cyclin-dependent kinases 7/9 (CDK7/9). It specifically targets CDK7, while also displaying inhibitory activity against CDK9. CDK7/9-IN-1 demonstrates excellent inhibitory potency ag... |
|
T10743 |
CDK9-IN-11
|
|
CDK
|
|
CDK9-IN-11 is a potent CDK9 inhibitor that is the ligand for the PROTAC CDK9 Degrader-1 [1]. |
|
T10741 |
CDK9-IN-1
|
|
CDK
|
|
CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection (IC50: 39 nM for CDK9/CycT1). |
|
T39354 |
CDK9-IN-12
|
CDK9-IN-12 |
|
|
CDK9-IN-12 displays the optimal CDK9 inhibitory activity with an IC 50 value of 5.41 nM. |
|
T79404 |
A09-003
|
|
Apoptosis
,
BCL
,
CDK
|
|
A09-003 is a novel cell cycle protein-dependent kinase-9 CDK-9 inhibitor.A09-003 inhibits the proliferation of a variety of leukemia cell lines and inhibits the increase of leukemia sequence-1 protein in myeloid cells.A0... |
|
T62791 |
CDK7-IN-16
|
|
|
|
CDK7-IN-16 (Compound 9) is a potent inhibitor of CDK 7 (IC50: 1-10 nM). CDK7-IN-16 can be used in research against cancer, particularly cancers with transcriptional abnormalities. |
|
T27033 |
CKD-712
|
CKD 712,CKD712 |
|
|
CKD-712 is a nuclear factor NF-kappa B inhibitor. CKD-712 suppressed MMP-9, but not MMP-2 and other NF-κB-regulated proteins involved in cancer metastasis such as VEGF. CKD-712 induced cell cycle arrest at G2M phase by s... |
|
T70897 |
Zotiraciclib HCl
|
|
|
|
Zotiraciclib, also known as TG02 and SB1317, is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting M... |
|
T70988 |
Ibulocydine
|
|
|
|
Ibulocydine is a potent CDK inhibitor. Ibulocydine has high activity against Cdk7/cyclin H/Mat1 and Cdk9/cyclin T. Ibulocydine inhibited the growth of HCC cells more effectively than other Cdk inhibitors, including olomo... |
|
T72951 |
CDK4/6-IN-14
|
|
|
|
CDK4/6-IN-14 is a potent, highly selective inhibitor of Cyclin-Dependent Kinases 4 and 6 (CDK4/6), demonstrating inhibition concentrations (IC50s) of 10 nM and 16 nM, respectively. It possesses over 60-fold greater selec... |
